Evidence map›Paper›PMID 42093002›Full record

ArticleOrphanet journal of rare diseases2026

Quality of life in children and adults with epidermolysis bullosa: the QoL-REB explorative study.

Cinzia Pilo, Laura Benedan, Valentina Morra, El Hachem M, Gianluca Tadini, Giuseppina Annicchiarico, Michela Brena, Sophie Guez, Lucia Lospalluti, Isabella L C Mariani Wigley and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Cinzia PiloFondazione REB, Milano, Italy.
Laura BenedanDepartment of Economics, Management and Statistics (DEMS), University of Milano-Bicocca, Milan, Italy.
Valentina MorraFondazione REB, Milano, Italy.
El Hachem MDermatology Unit, Genodermatosis Research Unit, Translational Paediatrics and Clinical Genetics Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Gianluca TadiniCenter for Hereditary Skin Diseases, Pediatric Dermatology Unit, University of Milan, Ospedale Maggiore Policlinico, Milan, Italy.
Giuseppina AnnicchiaricoRegional Coordination of Rare Diseases (CoReMaR), Apulia Regional Agency for Health and Social Care (AReSS), Bari, Italy.
Michela BrenaPediatric Dermatology Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Sophie GuezPediatric-Pneumoinfectivology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Pediatrics, Milan, Italy.
Lucia LospallutiDermatology Department, Azienda Universitario Ospedaliera Policlinico of Bari, Bari, Italy.
Isabella L C Mariani WigleyFinnBrain Birth Cohort Study, Turku Brain and Mind Center, University of Turku, Kiinamyllynkatu 10, Turku, 20520, Finland. ilmawi@utu.fi.ORCID http://orcid.org/0000-0003-0958-5124
Livio ProvenziDevelopmental Psychobiology Lab, Department of Brain and Behavioural Sciences, University of Pavia, IRCCS Mondino Foundation, Pavia, Italy.
Paolo Mariani *Department of Economics, Management and Statistics (DEMS), University of Milano-Bicocca, Milan, Italy.
Serena Barello *WHYpsy Lab, Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.

Funding

Fondazione REB QoL-REB
6 · The paper itself

Abstract

backgroundEpidermolysis bullosa (EB) is a rare inherited disorder characterized by skin and mucosal fragility, with severe implications for physical, psychological, and social well-being. Research on quality of life (QoL) in EB remains limited, particularly in Italy, where systematic patient-reported outcome measures are lacking. To address this gap, Fondazione REB ETS developed a patient-centered QoL questionnaire (QoL-REB) constructed directly by patients and caregivers, with support from clinicians and researchers.

methodsWe conducted a cross-sectional online survey between March and April 2024, recruiting Italian EB patients and caregivers through Fondazione REB and Debra Italia mailing lists. Participants completed the QoL-REB questionnaire, which assesses seven dimensions of QoL: physical health, autonomy, emotional well-being, family dynamics, social interactions, work/school life, and care experience. Responses were rated on a 4-point scale, with overall QoL assessed on a 0-10 scale.

resultsForty-seven individuals with EB (38 adults, 9 minors; 55% female) participated, representing multiple EB subtypes, predominantly dystrophic EB (62.4%). Mean overall QoL was rated 6/10. Pain, itching, and reduced mobility emerged as the most frequent physical challenges. Over 70% of adults reported limited autonomy in daily activities, while children experienced difficulties with walking, dressing, and sports participation. Emotional distress was common, with patients expressing concerns about future prospects, body image, and dependence on others; 43% reported a need for psychological support. Family burden was evident, with both adults and minors perceiving themselves as a strain on relatives. Social limitations, workplace and school difficulties, and dissatisfaction with healthcare services-particularly a lack of EB-specific expertise in non-reference centers-were also reported.

conclusionsThis first Italian patient-led assessment highlights the pervasive and multidimensional burden of EB on QoL. Findings underscore the need for integrated, patient-centered care models that combine medical, psychological, and social support. The QoL-REB questionnaire provides a novel, comprehensive tool to capture the lived experience of EB and may serve as a framework for international adaptation and implementation.

Indexed as

Epidermolysis BullosaQuality of LifeAdolescentAdultCaregiversChildChild, PreschoolCross-Sectional StudiesFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresSurveys and QuestionnairesYoung AdultEpidermolysis bullosaPatient-centered researchPatient-reported outcomesQuality of lifeRare diseases

Identifiers

PMID42093002
PMCPMC13151378

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.